Amuvatinib
Information
- Drug Name
- Amuvatinib
- Description
- Entry(CIViC)
- 1
CIViC
Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
skin melanoma | NRAS MUTATION NRAS MUTATION | D |
![]() |
![]() |
Sensitivity/Response | Somatic | 1 | 24950457 | Detail |
Annotation
Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
---|---|---|---|---|---|---|
Preclinical study in melanoma cell lines. Cell lin... | NRAS | NRAS MUTATION NRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT01357395 | Completed | Phase 2 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | May 2011 | May 28, 2012 |
- Target (Drug list of Screening Committee of Anticancer Drugs)
- PDGFR
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- MP-470
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- HPK-56
- Target (Drug list of Screening Committee of Anticancer Drugs)
- c-Kit
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- MP-470
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- HPK-56
- Target (Drug list of Screening Committee of Anticancer Drugs)
- c-Met
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- MP-470
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- HPK-56
- Target (Drug list of Screening Committee of Anticancer Drugs)
- FLT3
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- MP-470
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- HPK-56
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Ret
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- MP-470
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- HPK-56